Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/29/12 → 10/21/17 |
Funding
- Boehringer Ingelheim Pharmaceutical: $48,221.33
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy ..Chemo-Radiotherapy.Stage III, Head & Neck Squamous Cell Carcinoma
- Keresztes, Roger (PI)
- Kudelka, Andrzej (CoPI)
- Valentine, Edward (CoPI)
Project: Research